<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460355</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Impact of Immunosuppressants and Vaccination on COVID-19 Outcomes in Autoimmune Patients and Solid Organ Transplant Recipients: A Nationwide Propensity Score-Matched Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1190</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101190</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study investigates the impact of varying degrees of immunosuppression on the clinical outcomes of immunocompromised individuals, particularly those with autoimmune diseases or post-solid organ transplant statuses, in the context of COVID-19. By focusing on these highly vulnerable populations, the study underscores the significant health inequalities faced by immunocompromised patients, who experience disproportionately worse outcomes in comparison to the general population.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective cohort analysis of the K-COV-N dataset was conducted, comparing the effects of immunosuppression in autoimmune and transplant groups with matched control groups. Propensity score matching was employed to minimize inequalities in baseline characteristics, ensuring a more equitable comparison between immunocompromised and non-immunocompromised individuals. Outcomes included COVID-19-related in-hospital mortality, 28-day mortality, ICU admissions, and the need for respiratory support among 323,890 adults in the Republic of Korea. Patients with cancer or other immunosuppressive conditions, such as HIV, were excluded. Subgroup analyses assessed the influence of specific immunosuppressive medications and vaccination extent.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Significantly elevated in-hospital mortality was found for patients with autoimmune diseases (adjusted Odds Ratio [aOR] 2.749) and transplant recipients (aOR 7.567), with similar patterns in other outcomes. High-dose steroid use and a greater number of immunosuppressant medications markedly increased the risk of poor outcomes. Vaccination emerged as a protective factor, with a single dose substantially improving outcomes for autoimmune patients and at least two doses necessary for transplant recipients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Immunocompromised patients, particularly those with autoimmune diseases and transplant recipients, are highly vulnerable to severe COVID-19 outcomes. High-dose steroid use and multiple immunosuppressants further increase risks. Vaccination significantly improves outcomes, with at least one dose benefiting autoimmune patients and two doses necessary for transplant recipients. Personalized vaccination schedules based on immunosuppression levels are essential to mitigate healthcare inequalities and improve outcomes, particularly in underserved populations, informing both clinical and public health strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sung</LastName><ForeName>Mindong</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5217-8877</Identifier><AffiliationInfo><Affiliation>Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Young-Sam</ForeName><Initials>YS</Initials><Identifier Source="ORCID">0000-0001-9656-8482</Identifier><AffiliationInfo><Affiliation>Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Changjin</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0002-8848-1736</Identifier><AffiliationInfo><Affiliation>Department of Information Statistics, Gyeongsang National University, Jinju 52828, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Son</LastName><ForeName>Yongeun</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0002-3027-2560</Identifier><AffiliationInfo><Affiliation>Department of Information Statistics, Gyeongsang National University, Jinju 52828, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Dong-Wook</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0002-4478-3794</Identifier><AffiliationInfo><Affiliation>Department of Information Statistics, Gyeongsang National University, Jinju 52828, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Information and Statistics, Research Institute of Natural Science, Gyeongsang National University, 501 Jinju-daero, Jinju 52858, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Su-Hwan</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0002-3487-2574</Identifier><AffiliationInfo><Affiliation>Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Bio &amp; Medical Bigdata (BK21 Plus), Gyeongsang National University, Jinju 52828, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RS-2020-KD000032</GrantID><Agency>Korean government (the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health &amp; Welfare, the Ministry of Food and Drug Safety)</Agency><Country /></Grant><Grant><GrantID>RS-2023-00252863</GrantID><Agency>National Research Foundation of Korea</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">autoimmune disease</Keyword><Keyword MajorTopicYN="N">immunocompromised</Keyword><Keyword MajorTopicYN="N">solid organ transplantation</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460355</ArticleId><ArticleId IdType="pmc">PMC11512354</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101190</ArticleId><ArticleId IdType="pii">vaccines12101190</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y., Ren R., Leung K.S.M., Lau E.H.Y., Wong J.Y., et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N. Engl. J. Med. 2020;382:1199–1207. doi: 10.1056/NEJMoa2001316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001316</ArticleId><ArticleId IdType="pmc">PMC7121484</ArticleId><ArticleId IdType="pubmed">31995857</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Miarons M., Larrosa-García M., García-García S., Los-Arcos I., Moreso F., Berastegui C., Castells L., Pérez-Hoyos S., Varela J., Pau-Parra A., et al. COVID-19 in Solid Organ Transplantation: A Matched Retrospective Cohort Study and Evaluation of Immunosuppression Management. Transplantation. 2021;105:138–150. doi: 10.1097/TP.0000000000003460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000003460</ArticleId><ArticleId IdType="pubmed">32941394</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavez-MacGregor M., Lei X., Zhao H., Scheet P., Giordano S.H. Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients with or Without Cancer. JAMA Oncol. 2022;8:69–78. doi: 10.1001/jamaoncol.2021.5148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2021.5148</ArticleId><ArticleId IdType="pmc">PMC8554684</ArticleId><ArticleId IdType="pubmed">34709356</ArticleId></ArticleIdList></Reference><Reference><Citation>Bytyci J., Ying Y., Lee L.Y.W. Immunocompromised Individuals Are at Increased Risk of COVID-19 Breakthrough Infection, Hospitalization, and Death in the Post-Vaccination Era: A Systematic Review. Immun. Inflamm. Dis. 2024;12:e1259. doi: 10.1002/iid3.1259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.1259</ArticleId><ArticleId IdType="pmc">PMC11044684</ArticleId><ArticleId IdType="pubmed">38661301</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek M.S., Lee M.-T., Kim W.-Y., Choi J.C., Jung S.-Y. COVID-19-Related Outcomes in Immunocompromised Patients: A Nationwide Study in Korea. PLoS ONE. 2021;16:e0257641. doi: 10.1371/journal.pone.0257641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0257641</ArticleId><ArticleId IdType="pmc">PMC8486114</ArticleId><ArticleId IdType="pubmed">34597325</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson E.J., Walker A.J., Bhaskaran K., Bacon S., Bates C., Morton C.E., Curtis H.J., Mehrkar A., Evans D., Inglesby P., et al. Factors Associated with COVID-19-Related Death Using OpenSAFELY. Nature. 2020;584:430–436. doi: 10.1038/s41586-020-2521-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen K.M., Mehta H.B., Palamuttam N., Ford D., Garibaldi B.T., Auwaerter P.G., Segal J., Alexander G.C. Association Between Chronic Use of Immunosuppresive Drugs and Clinical Outcomes From Coronavirus Disease 2019 (COVID-19) Hospitalization: A Retrospective Cohort Study in a Large US Health System. Clin. Infect. Dis. 2021;73:e4124–e4130. doi: 10.1093/cid/ciaa1488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1488</ArticleId><ArticleId IdType="pmc">PMC7953980</ArticleId><ArticleId IdType="pubmed">33410884</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin Y.H., Shin J.I., Moon S.Y., Jin H.Y., Kim S.Y., Yang J.M., Cho S.H., Kim S., Lee M., Park Y., et al. Autoimmune Inflammatory Rheumatic Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study. Lancet Rheumatol. 2021;3:e698–e706. doi: 10.1016/S2665-9913(21)00151-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00151-X</ArticleId><ArticleId IdType="pmc">PMC8213376</ArticleId><ArticleId IdType="pubmed">34179832</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama S., Hamdeh S., Micic D., Sakuraba A. Prevalence and Clinical Outcomes of COVID-19 in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis. Ann. Rheum. Dis. 2021;80:384–391. doi: 10.1136/annrheumdis-2020-218946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218946</ArticleId><ArticleId IdType="pubmed">33051220</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolla E., Weill A., Zaidan M., De Martin E., Colin De Verdiere S., Semenzato L., Zureik M., Grimaldi L. COVID-19 Hospitalization in Solid Organ Transplant Recipients on Immunosuppressive Therapy. JAMA Netw. Open. 2023;6:e2342006. doi: 10.1001/jamanetworkopen.2023.42006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.42006</ArticleId><ArticleId IdType="pmc">PMC10630896</ArticleId><ArticleId IdType="pubmed">37934496</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadi Y.B., Naqvi S.F.Z., Kupec J.T., Sofka S., Sarwari A. Outcomes of COVID-19 in Solid Organ Transplant Recipients: A Propensity-Matched Analysis of a Large Research Network. Transplantation. 2021;105:1365–1371. doi: 10.1097/TP.0000000000003670.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000003670</ArticleId><ArticleId IdType="pmc">PMC8414593</ArticleId><ArticleId IdType="pubmed">33988341</ArticleId></ArticleIdList></Reference><Reference><Citation>Cravedi P., Mothi S.S., Azzi Y., Haverly M., Farouk S.S., Pérez-Sáez M.J., Redondo-Pachónet M.D., Murphy B., Florman S., Cyrino L.G., et al. COVID-19 and Kidney Transplantation: Results from the TANGO International Transplant Consortium. Am. J. Transplant. 2020;20:3140–3148. doi: 10.1111/ajt.16185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.16185</ArticleId><ArticleId IdType="pmc">PMC7405285</ArticleId><ArticleId IdType="pubmed">32649791</ArticleId></ArticleIdList></Reference><Reference><Citation>Kates O.S., Haydel B.M., Florman S.S., Rana M.M., Chaudhry Z.S., Ramesh M.S., Safa K., Kotton C.N., Blumberg E.A., Besharatian B.D., et al. COVID-19 in Solid Organ Transplant: A Multi-Center Cohort Study. Clin. Infect. Dis. 2021;35:100588. doi: 10.1093/cid/ciaa1097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1097</ArticleId></ArticleIdList></Reference><Reference><Citation>Raja M.A., Mendoza M.A., Villavicencio A., Anjan S., Reynolds J.M., Kittipibul V., Fernandez A., Guerra G., Camargo J.F., Simkins J., et al. COVID-19 in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis of Current Literature. Transplant. Rev. 2020;35:100588. doi: 10.1016/j.trre.2020.100588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trre.2020.100588</ArticleId><ArticleId IdType="pmc">PMC7666542</ArticleId><ArticleId IdType="pubmed">33246166</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin C.X., Moore L.W., Anjan S., Rahamimov R., Sifri C.D., Ali N.M., Morales M.K., Tsapepas D.S., Basic-Jukic N., Miller R.A., et al. Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients. Transplantation. 2021;105:e265–e266. doi: 10.1097/TP.0000000000003907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000003907</ArticleId><ArticleId IdType="pmc">PMC8549120</ArticleId><ArticleId IdType="pubmed">34310531</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinde V., Bhikha S., Hoosain Z., Archary M., Bhorat Q., Fairlie L., Lalloo U., Masilela M.S.L., Moodley D., Hanley S., et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N. Engl. J. Med. 2021;384:1899–1909. doi: 10.1056/NEJMoa2103055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2103055</ArticleId><ArticleId IdType="pmc">PMC8091623</ArticleId><ArticleId IdType="pubmed">33951374</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty C., Bhattacharya M., Dhama K. SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic. Vaccines. 2023;11:682. doi: 10.3390/vaccines11030682.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11030682</ArticleId><ArticleId IdType="pmc">PMC10054865</ArticleId><ArticleId IdType="pubmed">36992266</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyarsky B.J., Werbel W.A., Avery R.K., Tobian A.A., Massie A.B., Segev D.L., Garonzik-Wang J.M. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. JAMA. 2021;325:1784–1786. doi: 10.1001/jama.2021.4385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.4385</ArticleId><ArticleId IdType="pmc">PMC7961463</ArticleId><ArticleId IdType="pubmed">33720292</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyarsky B.J., Werbel W.A., Avery R.K., Tobian A.A.R., Massie A.B., Segev D.L., Garonzik-Wang J.M. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA. 2021;325:2204–2206. doi: 10.1001/jama.2021.7489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.7489</ArticleId><ArticleId IdType="pmc">PMC8100911</ArticleId><ArticleId IdType="pubmed">33950155</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A.R.Y.B., Wong S.Y., Chai L.Y.A., Lee S.C., Lee M.X., Muthiah M.D., Tay S.H., Teo C.B., Tan B.K.J., Chan Y.H., et al. Efficacy of Covid-19 Vaccines in Immunocompromised Patients: Systematic Review and Meta-Analysis. BMJ. 2022;376:e068632. doi: 10.1136/bmj-2021-068632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068632</ArticleId><ArticleId IdType="pmc">PMC8889026</ArticleId><ArticleId IdType="pubmed">35236664</ArticleId></ArticleIdList></Reference><Reference><Citation>Napuri N.I., Curcio D., Swerdlow D.L., Srivastava A. Immune Response to COVID-19 and mRNA Vaccination in Immunocompromised Individuals: A Narrative Review. Infect. Dis. Ther. 2022;11:1391–1414. doi: 10.1007/s40121-022-00648-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-022-00648-2</ArticleId><ArticleId IdType="pmc">PMC9132351</ArticleId><ArticleId IdType="pubmed">35614299</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised.  [(accessed on 8 July 2024)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html.</Citation></Reference><Reference><Citation>Immunocompromised.  [(accessed on 8 July 2024)]; Available online:  https://www.covid19treatmentguidelines.nih.gov/special-populations/immunocompromised/</Citation></Reference><Reference><Citation>Tenforde M.W., Patel M.M., Ginde A.A., Douin D.J., Talbot H.K., Casey J.D., Mohr N.M., Zepeski A., Gaglani M., McNeal T., et al. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States. Clin. Infect. Dis. 2021;74:1515–1524. doi: 10.1093/cid/ciab687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab687</ArticleId><ArticleId IdType="pmc">PMC8436392</ArticleId><ArticleId IdType="pubmed">34358310</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung M., Babik J.M. COVID-19 in Immunocompromised Hosts: What We Know So Far. Clin. Infect. Dis. 2021;72:340–350. doi: 10.1093/cid/ciaa863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa863</ArticleId><ArticleId IdType="pmc">PMC7337668</ArticleId><ArticleId IdType="pubmed">33501974</ArticleId></ArticleIdList></Reference><Reference><Citation>Galmiche S., Luong Nguyen L.B., Tartour E., De Lamballerie X., Wittkop L., Loubet P., Launay O. Immunological and Clinical Efficacy of COVID-19 Vaccines in Immunocompromised Populations: A Systematic Review. Clin. Microbiol. Infect. 2022;28:163–177. doi: 10.1016/j.cmi.2021.09.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.09.036</ArticleId><ArticleId IdType="pmc">PMC8595936</ArticleId><ArticleId IdType="pubmed">35020589</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Ayada I., Wang Y., den Hoed C.M., Kamar N., Peppelenbosch M.P., de Vries A.C., Li P., Pan Q. Factors Associated with COVID-19 Vaccine Response in Transplant Recipients: A Systematic Review and Meta-Analysis. Transplantation. 2022;106:2068–2075. doi: 10.1097/TP.0000000000004256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000004256</ArticleId><ArticleId IdType="pmc">PMC9521391</ArticleId><ArticleId IdType="pubmed">35761439</ArticleId></ArticleIdList></Reference><Reference><Citation>Aslam S., Adler E., Mekeel K., Little S.J. Clinical Effectiveness of COVID-19 Vaccination in Solid Organ Transplant Recipients. Transpl. Infect. Dis. 2021;23:e13705. doi: 10.1111/tid.13705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tid.13705</ArticleId><ArticleId IdType="pmc">PMC8420394</ArticleId><ArticleId IdType="pubmed">34324256</ArticleId></ArticleIdList></Reference><Reference><Citation>Embi P.J., Levy M.E., Naleway A.L., Patel P., Gaglani M., Natarajan K., Dascomb K., Ong T.C., Klein N.P., Liao I.-C., et al. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines against COVID-19–Associated Hospitalizations among Immunocompromised Adults—Nine States, January–September 2021. MMWR Morb. Mortal. Wkly. Rep. 2021;70:1553–1559. doi: 10.15585/mmwr.mm7044e3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7044e3</ArticleId><ArticleId IdType="pmc">PMC8568092</ArticleId><ArticleId IdType="pubmed">34735426</ArticleId></ArticleIdList></Reference><Reference><Citation>Meredith R.T., Bermingham M.D., Bentley K., Agah S., Aboagye-Odei A., Yarham R.A.R., Mills H., Shaikh M., Hoye N., Stanton R.J., et al. Differential Cellular and Humoral Immune Responses in Immunocompromised Individuals following Multiple SARS-CoV-2 Vaccinations. Front. Cell. Infect. Microbiol. 2023;13:1207313. doi: 10.3389/fcimb.2023.1207313.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2023.1207313</ArticleId><ArticleId IdType="pmc">PMC10327606</ArticleId><ArticleId IdType="pubmed">37424787</ArticleId></ArticleIdList></Reference><Reference><Citation>Manothummetha K., Chuleerarux N., Sanguankeo A., Kates O.S., Hirankarn N., Thongkam A., Dioverti-Prono M.V., Torvorapanit P., Langsiri N., Worasilchai N., et al. Immunogenicity and Risk Factors Associated with Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant. JAMA Netw. Open. 2022;5:e226822. doi: 10.1001/jamanetworkopen.2022.6822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.6822</ArticleId><ArticleId IdType="pmc">PMC9006106</ArticleId><ArticleId IdType="pubmed">35412626</ArticleId></ArticleIdList></Reference><Reference><Citation>Hütter-Krönke M.L., Neagoie A., Blau I.W., Wais V., Vuong L., Gantner A., Ahn J., Penack O., Schnell J., Nogai K.A., et al. Risk Factors and Characteristics Influencing Humoral Response to COVID-19 Vaccination in Patients after Allogeneic Stem Cell Transplantation. Front. Immunol. 2023;14:1174289. doi: 10.3389/fimmu.2023.1174289.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1174289</ArticleId><ArticleId IdType="pmc">PMC10190126</ArticleId><ArticleId IdType="pubmed">37207199</ArticleId></ArticleIdList></Reference><Reference><Citation>Schönlein M., Wrage V., Ghandili S., Mellinghoff S.C., Brehm T.T., Leypoldt L.B., Utz N., Schrader R.M., Alsdorf W., Börschel N., et al. Risk Factors for Poor Humoral Response to Primary and Booster SARS-CoV-2 Vaccination in Hematologic and Oncological Outpatients—COVIDOUT Study. Cancer Cell. 2022;40:581–583. doi: 10.1016/j.ccell.2022.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2022.04.016</ArticleId><ArticleId IdType="pmc">PMC9040439</ArticleId><ArticleId IdType="pubmed">35512712</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeigue P.M., McAllister D.A., Hutchinson S.J., Robertson C., Stockton D., Colhoun H.M. Vaccine Efficacy against Severe COVID-19 in Relation to Delta Variant (B.1.617.2) and Time since Second Dose in Patients in Scotland (REACT-SCOT): A Case-Control Study. Lancet Respir. Med. 2022;10:566–572. doi: 10.1016/S2213-2600(22)00045-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00045-5</ArticleId><ArticleId IdType="pmc">PMC8880999</ArticleId><ArticleId IdType="pubmed">35227416</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang P., Hasan M.R., Chemaitelly H., Yassine H.M., Benslimane F.M., Al Khatib H.A., AlMukdad S., Coyle P., Ayoub H.H., Al Kanaani Z., et al. BNT162b2 and mRNA-1273 COVID-19 Vaccine Effectiveness against the SARS-CoV-2 Delta Variant in Qatar. Nat. Med. 2021;27:2136–2143. doi: 10.1038/s41591-021-01583-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01583-4</ArticleId><ArticleId IdType="pubmed">34728831</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim I.-H., No J.S., Kim J.-A., Park A.K., Lee H., Kim J.-M., Lee N.-J., Kim C.-K., Lee C.Y., Woo S., et al. Genomic Epidemiology of SARS-CoV-2 Variants in South Korea between January 2020 and February 2023. Virology. 2023;587:109869. doi: 10.1016/j.virol.2023.109869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2023.109869</ArticleId><ArticleId IdType="pubmed">37673001</ArticleId></ArticleIdList></Reference><Reference><Citation>Samieefar N., Rashedi R., Akhlaghdoust M., Mashhadi M., Darzi P., Rezaei N. Delta Variant: The New Challenge of COVID-19 Pandemic, an Overview of Epidemiological, Clinical, and Immune Characteristics. Acta Biomed. Atenei Parm. 2022;93:e2022179. doi: 10.23750/abm.v93i1.12210.</Citation><ArticleIdList><ArticleId IdType="doi">10.23750/abm.v93i1.12210</ArticleId><ArticleId IdType="pmc">PMC8972886</ArticleId><ArticleId IdType="pubmed">35315394</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon J., Chin B. Treatment Options for Patients with Mild-to-Moderate Coronavirus Disease 2019 in Korea. J. Korean Med. Sci. 2022;37:e352. doi: 10.3346/jkms.2022.37.e352.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2022.37.e352</ArticleId><ArticleId IdType="pmc">PMC9745683</ArticleId><ArticleId IdType="pubmed">36513054</ArticleId></ArticleIdList></Reference><Reference><Citation>Park D.H., Kang C.K., Choe P.G., Kim N.J., Park W.B., Oh M. How We Have Treated Severe to Critically Ill Patients with Coronavirus Disease 2019 in Korea. J. Korean Med. Sci. 2022;37:e353. doi: 10.3346/jkms.2022.37.e353.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2022.37.e353</ArticleId><ArticleId IdType="pmc">PMC9763707</ArticleId><ArticleId IdType="pubmed">36536547</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>